Sareum (SAR) Share Price, News & Analysis

Company Overview

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases. Its also developing SDC-1802, a TYK2/JAK1 inhibitor, which is in preclinical stage for cancerandcancer-immunotherapy applications; and SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.

Key Stats

• Today's Range: 25.30 to 27
• 50-Day Range: 23.41 to 31
• 52-Week Range: 10 to 78
• Volume: 39,066 shs
• Average Volume: 703,505 shs
• Market Capitalization: £29.15 million
• P/E Ratio: N/A
• Dividend Yield: 1.10%
• Price Target: N/A
• Consensus Rating: N/A

SAR Stock Analysis - Frequently Asked Questions

How have SAR shares performed this year?

Sareum's stock was trading at GBX 59.50 on January 1st, 2024. Since then, SAR shares have decreased by 54.6% and is now trading at GBX 27.
View the best growth stocks for 2024 here.

How do I buy shares of Sareum?

Shares of SAR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Sareum own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sareum investors own include ReNeuron Group (RENE), ValiRx (VAL), Sierra Oncology (SRRA), Egdon Resources (EDR), Collagen Solutions plc (COS.L) (COS), Gulf Keystone Petroleum (GKP) and Summit Therapeutics (SMMT).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Financial Services
• Current Symbol: LON:SAR
• CUSIP: N/A
• CIK: N/A
• Web: www.sareum.co.uk
• Phone: +44-1223-497700
• Fax: N/A
• Employees: 3,211
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-4,250,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -257.72%
• Return on Assets: -113.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.93
• Quick Ratio: 10.37

Sales & Book Value

• Annual Sales: £47,204.00
• Price / Sales: 617.46
• Cash Flow: GBX 2.38 per share
• Price / Cash Flow: 11.32
• Book Value: GBX 1 per share
• Price / Book: 27.00

Miscellaneous

• Outstanding Shares: 107,950,000
• Free Float: N/A
• Market Cap: £29.15 million
• Optionable: Not Optionable
• Beta: -1.08